KaydedilenlerDerginizi ekleyin

Dergiler / Addicta: The Turkish Journal on Addictions / 2021 / Cilt: 8 - Sayı: 1

The Success of Smoking Cessation Treatments: The Gulhane Experience

Yakup ARSLAN
Nesrin ÖCAL
Ahmet ÇAĞIN
Deniz DOGAN
Cantürk TAŞÇI
Sayfa
8–15
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The reliability of varenicline, low FTND level, absence of comorbidity, and increased numbers follow-up visits were found to be contributing factors to this success.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:This study aimed to evaluate the success and factors that affected the success of smoking cessation treatments adopted in the Gulhane Smoking Cessation Polyclinic (SCP).
📊
Temel Bulgular & Veri:The smokers admitted to SCP from January 1, 2018, to July 15, 2019, were included in the study.
💡
Sonuç & Katkı:The reliability of varenicline, low FTND level, absence of comorbidity, and increased numbers follow-up visits were found to be contributing factors to this success.
🔬Tür:Araştırma Makalesi
📍Kapsam:2018 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

This study aimed to evaluate the success and factors that affected the success of smoking cessation treatments adopted in the Gulhane Smoking Cessation Polyclinic (SCP). The smokers admitted to SCP from January 1, 2018, to July 15, 2019, were included in the study. The participants were treated with varenicline or nicotine replacement therapy (NRT) combined with cognitive behavioral therapy (CBT). The number of all participants was 598, and 196 (32.8%) of them quitted smoking successfully. The varenicline group (n=264) had significantly higher number and percentage of participants who successfully quit smoking than the NRT group (n=334), which accounted for 113 (42.8%) and 83 (24.9%), respectively (p<0.001). The highest smoking cessation rate was detected in the group with low Fagerström Test for Nicotine Dependence (FTND) at 79.5% (p<0.001). Participants without comorbidity had higher smoking cessation rates than others (p=0.002). The mean numbers of follow-up visits were higher in the successfully quit group with a mean number of 4.2 (p<0.001). CBT combined with varenicline was found to be more successful than CBT combined with NRT in smoking cessation. The reliability of varenicline, low FTND level, absence of comorbidity, and increased numbers follow-up visits were found to be contributing factors to this success.

🔖

Bu Makaleye Atıf Yap

ARSLAN, Y., ÖCAL, N., ÇAĞIN, A., DOGAN, D., TAŞÇI, C. (2021). The Success of Smoking Cessation Treatments: The Gulhane Experience. Addicta: The Turkish Journal on Addictions, Cilt: 8 - Sayı: 1, 8–15. https://ajindex.com/articles/357257

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Akkaya, A., Ozturk, O., Cobanoglu, H., Bircan, HA., Simsek, S., & Sahin U. (2006). Evaluation of patients followed up in a cigarette cessation clinic. Respirology, 11(3), 311-316.
  2. Arguder, E., Karalezli, A., Hezer, H., Kılıc, H., Er, M., Hasanoglu, H. C., & Demir, P. (2013). Factors Affecting the Success of Smoking Cessation. Turkish Thoracic Journal, 14, 81-87.
  3. Arslan, Y., Ocal, N., Dogan, D., Cagın, A., Tascı, C., & Sarı, O. (2021). The awareness of chronic obstructive pulmonary disease among smokers admitting to pulmonary medicine outpatient clinic: Single center experience. Gulhane Medical Journal, 63, 59-67.
  4. Aytemur, Solak, Z., Gunduz, Telli, C., & Erdinc, E. (2003). Results of smoking cessation treatment. Toraks Dergisi, 4(1), 73-77.
  5. Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016). Nicotine receptor partial agonists for smoking cessation. The Cochrane Database of Systematic Reviews, 5, CD006103. Calikoglu, EO., & Koycegiz, E. (2019). Tobacco Control Policies in Turkey in Terms of MPOWER. The Eurasian Journal of Medicine, 51(1), 80-84.
  6. Can, G., Oztuna, F., & Ozlu, T. (2004). The evaluation of outpatient smoking cessation clinic results. Tüberküloz ve Toraks, 52(1), 69-74.
  7. Celik, I., Yuce, D., Hayran, M., Erman, M., Kılıckap, S., Buzgan, T., Irmak, H., Tosun, N., Tuncer, M., & Akdağ, R. (2015). Nationwide smoking cessation treatment support program-Turkey project. Health Policy, 1, 50-56.
  8. Demir, T., Tutluoglu, B., Koc, N., & Bilgin, L. (2004). Oneyear follow up results of smoking cessation outpatient clinic. Tüberküloz ve Toraks, 52(1), 63-8.
  9. Dubray, J., Schwartz, R., Chaiton, M., O’Connor, S., & Cohen, J. E. (2015). The effect of MPOWER on smoking prevalence. Tobacco Control, 24(6), 540-542.
  10. Ebbert, J. O., Hughes, J. R., West, R. J., Rennard, I. S., Russ, C., Macrae, T. D., Treadow, J., You, C. R., Dutro, M. P., & Park, P. W. (2015). Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA, 313(7), 687-694.
  11. Fiore, M. C., Jaén, C. R., Baker, T. B., Bailey, W. C., Benowitz, N. L., & Curry, S. J. (2008). Treating tobacco use and dependence: 2008 Update U.S. Public Health Service Clinical Practice Guideline executive summary. Respiratory Care, 53(9), 1217-1222. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. (2018). Global, regional, and national incidence, prevalence, and years lived with disabi lity for 354 diseases and injuries for 195 countries an